Company Statement on Vincristine

 

Patients are at the heart of everything we do at Teva and the Company takes very seriously the importance of vincristine. We share the passion and pain that healthcare providers, parents and patients feel when any product is unavailable that is critical to care. Which is why Teva determined in 2019 that it would re-introduce vincristine in the US as quickly as possible. Product became available for patients in the U.S. in early 2020 and remains available today.

When Teva removed vincristine from the US market there was no indication at all of a possible shortage. In fact, the company was only supplying 3% of the market and, without any information to the contrary, anticipated that that volume could quickly and easily be absorbed by the brand manufacturer, which was supplying the other 97%. 

We do not take the discontinuance of any product lightly, and we always evaluate the need for our product as thoroughly as possible before deciding to discontinue it (though we are generally not privy to the supply challenges that other manufacturers may be experiencing). 

Teva has a history of being a strong, responsible corporate partner and takes its commitment to patients seriously. Read more about our efforts in our latest ESG Progress Report.